The Decade of Progress in Lung Cancer: From Early Detection over Biomarker-Driven Diagnostics to Personalized Treatment Concepts
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 472
Special Issue Editors
Interests: lung emphysema; chronic obstructive lung disease; alpha 1 antitrypsin deficiency
Interests: lung cancer; screening/early detection; biomarkers; diagnostics; systemic therapies; quality of care; multidisciplinary team care
Special Issue Information
Dear Colleagues,
Worldwide, lung cancer is the second most common cancer and by far the leading cause of cancer-related death. Yet, over the last decade, substantial progress throughout the lung cancer continuum has led to improved outcomes and patient experiences. This Special Issue focuses on these multifaceted advances in diagnostics and therapeutics for lung cancer patients. While the implementation of population-based low-dose CT screening programmes will result in the long-awaited shift towards curable stages, modern diagnostic and therapeutic concepts integrate personalized approaches as well the latest therapeutics and technology into a multidisciplinary environment. We cordially invite the submission of research articles that will improve our knowledge of these topics. This commemorative Special Issue will publish original research and review articles.
Prof. Dr. Joanna Chorostowska-Wynimko
Dr. Torsten Gerriet Blum
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- screening
- early detection
- biomarkers
- diagnostics
- treatment
- multidisciplinary team care
